45. Lorbrena

Pfizer  headquarters logo sign
(Tracy Staton)

Active ingredient: lorlatinib 
Disease: ALK-positive non-small cell lung cancer 
Peak sales estimate: n/a
Approved: Nov. 2 
Company: Pfizer 

The scoop: Pfizer’s Xalkori is hammered by new competition in the ALK-positive lung cancer space, and that’s where Lorbrena comes in. The successor drug looks to analysts as though it may be more tolerable for patients when paired with fellow Pfizer cancer-fighter Bavencio than Xalkori is, and if the New York drugmaker can ultimately snag a combo approval, it would “represent a rare corner of the oncology market where Bavencio may have an advantage,” Credit Suisse’s Vamil Divan has said. In the meantime, Pfizer is looking to take Lorbrena—currently indicated only for previously treated patients—into the front-line setting. There, it would compete alongside Xalkori against Roche’s Alecensa and Novartis’ Zykadia, with Takeda’s Alunbrig also expected to jump into the mix sooner rather than later. — Carly Helfand 

45. Lorbrena

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.